Loading company…
Navrogen is a US biotechnology company developing antibody-drug conjugates and diagnostics to overcome immunosuppression in cancer.
Founded in 2017 in the United States, Navrogen develops therapeutic agents and diagnostic tools to counter immunosuppressive mechanisms in Humoral Immuno-Oncology. Its lead products include the antibody-drug conjugate NAV-001 and NAV-006, a next-generation rituximab, aimed at oncologists and healthcare professionals. Its revenue model relies on partnerships, milestone payments and potential royalties. It raised USD 3.00 mn in Seed funding on August 9, 2021, led by Tellus BioVentures, and CEO Nicholas Nicolaides leads the firm.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in